A Comprehensive Study of the Chemosensitizing Effects of AZD-1775, WEE-1 Inhibitor in Combination with DNA Damaging Treatments in the Jurkat Leukemia Cell Model

被引：0
|
作者：
Rodriguez, Gabriel Omar
Carrero, Ricardo
Diaz-Quinones, Adriana
Salgado, Iris
Silva, Walter
Maldonado, Hector
机构：
来源：
FASEB JOURNAL | 2019年 / 33卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
647.39
引用
收藏
页数：2
相关论文
共 17 条
  • [1] Synergistic Effects of Adavosertib, WEE-1 Inhibitor in Combination with Cytarabine in the Jurkat Leukemia Cell Model
    Rodriguez-Vazquez, Gabriel O.
    Diaz-Quinones, Adriana O.
    Salgado, Iris K.
    Ortiz, Walter I. Silva
    Maldonado, Hector M.
    FASEB JOURNAL, 2022, 36
  • [2] Anticancer and chemosensitization effects of Wee-1 kinase inhibitor Adavosertib (MK-1775; AZD-1775) in breast cancer cell lines
    Aviles, Nicole M. Nieves
    Diaz-Quinones, Adriana O.
    Salgado, Iris K.
    Silva, Walter
    Maldonado, Hector
    FASEB JOURNAL, 2022, 36
  • [3] Wee-1 kinase inhibitor AZD-1775 radiosensitizes esophageal cancer through targeting G2 checkpoint activation
    Yang, Linlin
    Pettit, Cory
    Hu, Andrew
    Li, Tianyun
    Williams, Terence M.
    CANCER RESEARCH, 2018, 78 (13)
  • [4] Anticancer and Chemosensitizing Effects of WEE-1 Kinase Inhibitor MK-1775 in Triple Negative (MB-231) Breast Cancer Cells
    Nieves Aviles, Nicole Marie
    Mayol, Noel
    Gonzalez, Maria T.
    Diaz, Adriana
    Salgado, Iris K.
    Silva, Walter
    Maldonado, Hector
    FASEB JOURNAL, 2019, 33
  • [5] EXPLOITING THE DNA DAMAGE RESPONSE (DDR) PATHWAY USING AZD-1775, A WEE1 INHIBITOR, TO SENSITIZE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS TO DIFFERENT ANTINEOPLASTIC DRUGS
    di Rora, A. Ghelli Luserna
    Beeharry, N.
    Imbrogno, E.
    Ferrari, A.
    Robustelli, V.
    Falzacappa, M. V.
    Ronchini, C.
    Testoni, N.
    Baldazzi, C.
    Papayannidis, C.
    Abbenante, M. C.
    Marconi, G.
    Hittle, J.
    Cavo, M.
    Iacobucci, I.
    Martinelli, G.
    Yen, T. J.
    HAEMATOLOGICA, 2017, 102 : 72 - 72
  • [6] ANTICANCER AND CHEMOSENSITIZING EFFECTS OF WEE-1 KINASE INHIBITOR MK-1775 IN TRIPLE NEGATIVE (MB-231) BREAST CANCER CELLS
    Aviles, Nicole M. Nieves
    Mayo, Noel
    Diaz-Quinones, Adriana O.
    Salgado, Iris K.
    Silva, Walter I.
    Maldonado, Hector M.
    FASEB JOURNAL, 2018, 32 (01):
  • [7] The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
    Lallo, Alice
    Frese, Kristopher K.
    Morrow, Christopher J.
    Sloane, Robert
    Gulati, Sakshi
    Schenk, Maximillian W.
    Trapani, Francesca
    Simms, Nicole
    Galvin, Melanie
    Brown, Stewart
    Hodgkinson, Cassandra L.
    Priest, Lynsey
    Hughes, Adina
    Lai, Zhongwu
    Cadogan, Elaine
    Khandelwal, Garima
    Simpson, Kathryn L.
    Miller, Crispin
    Blackhall, Fiona
    O'Connor, Mark J.
    Dive, Caroline
    CLINICAL CANCER RESEARCH, 2018, 24 (20) : 5153 - 5164
  • [8] Antitumor effects of WEE1 inhibitor, AZD1775 alone or in combination with PARP inhibitor in triple negative breast cancer cells
    Ha, Dong Hyeon
    Min, Arrum
    Kim, Seongyeong
    Kim, So Hyeon
    Jang, Hyemin
    Kim, Yu Jin
    Jung, Daeun
    Park, YoonJung
    Suh, Koung Jin
    Lee, Kyung-Hun
    Kim, Tae-Yong Kiim
    Im, Seock-Ah
    CANCER RESEARCH, 2018, 78 (13)
  • [9] THE INHIBITION OF THE DNA DAMAGE RESPONSE (DDR) USING THE WEE-1 INHIBITOR, MK-1775, SENSITIZES ACUTE LYMPHOBLASTIC LEUKEMIA CELLS TO THE TOXICITY OF DIFFERENT COMPOUNDS
    Di Rora, A. Ghelli Luserna
    Iacobucci, I.
    Beeharry, N.
    Imbrogno, E.
    Papayannidis, C.
    Robustelli, V.
    Ferrari, A.
    Guadagnuolo, V.
    Cavo, M.
    Martinelli, G.
    Yen, T. J.
    HAEMATOLOGICA, 2016, 101 : S68 - S68
  • [10] The WEE1 inhibitor AZD1775 in combination with chemotherapy in Asian patients with advanced solid tumors: a phase lb study
    Bang, Yung-Jue
    De Souza, Paul
    Kim, Sang-We
    Lickliter, Jason
    Naito, Yoichi
    Park, Keunchil
    Kumar, Sanjeev
    Mugundu, Ganesh M.
    Kato, Hidenori
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
12